Cantor Fitzgerald Reiterates “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “neutral” rating reissued by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $152.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 19.49% from the stock’s previous close.

Several other analysts have also recently commented on the company. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their target price for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Morgan Stanley restated an “overweight” rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. BMO Capital Markets upped their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. Finally, Robert W. Baird upped their price target on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. Three investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $187.39.

Sarepta Therapeutics Stock Performance

SRPT opened at $127.21 on Friday. The stock has a market cap of $12.02 billion, a PE ratio of 1,156.45 and a beta of 0.81. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $173.25. The stock’s 50 day simple moving average is $137.26 and its 200-day simple moving average is $132.66.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the previous year, the business posted ($0.27) earnings per share. Sarepta Therapeutics’s quarterly revenue was up 38.9% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 1.47 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 52,801 shares of company stock valued at $8,399,586. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after acquiring an additional 243,180 shares in the last quarter. Capital International Investors grew its holdings in shares of Sarepta Therapeutics by 1.6% during the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after buying an additional 76,032 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares in the last quarter. Wellington Management Group LLP grew its stake in Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock valued at $398,025,000 after purchasing an additional 217,810 shares in the last quarter. Finally, Farallon Capital Management LLC grew its stake in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.